Alvotech Advances Partnerships To Take Pipeline Global
Executive Summary
By the middle of this year, biosimilars developer Alvotech plans to have strategic alliances in place with a handful of regional partners to commercialize its pipeline of seven biosimilar monoclonal antibodies.
You may also be interested in...
Alvotech Differentiation Plans Include Interchangeable Golimumab
A proposal to merge with a special purpose acquisition company, in a move that will deliver longstanding plans for a public listing, has led biosimilars specialist Alvotech to discuss its ambitions and goals for its pipeline of seven biosimilar candidates.
Alvotech And Stada Make Biosimilars Pact
Alvotech and Stada have struck a deal that will give Stada exclusive rights to sell seven Alvotech biosimilars “in all key European markets” as well as certain other territories.
Sandoz Reveals Biosimilar Denosumab Program
As Sandoz reported its second-quarter financial results, the firm revealed details of a previously unannounced development program for biosimilar denosumab.